Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Feb 24, 2023 9:35pm
79 Views
Post# 35304812

RE:Protalix

RE:ProtalixYes, Protalix likely has a continuing relationship with Chiesi, as I post back in 2020. Therefore, Protalix likely has a relationship with Bioasis. 

Unfortunately, Bioasis has already been paid by Chiesi for its LSDs. Future developmental, regulatory and commercial milestone payments are set at an average of $34.5 million per LSD. There is also a royalty that can't come into play for many years.

So who TF cares what Chiesi is doing with non-xB3 drugs? Bioasis needs deals and money right now, not someday if approval of an xB3 version of PRX-102 is expected.

poof is trying to puff up the Chiesi thing. Unless Chiesi makes a deal right now with Bioasis for xB3-004 or something, then what Chiesi does is meaningless to Bioasis and its shareholders.

jd
<< Previous
Bullboard Posts
Next >>